Chen Yuanbin, Guo Liya, Jiao Yiqing, Fan Feiting, Liu Jian, Chen Ming, Yuan Huaiping, Lin Lin, Wang Yuguang
Department of Respiratory Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine and Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China.
Department of Respiratory Medicine, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, P.R. China.
Exp Ther Med. 2021 Apr;21(4):356. doi: 10.3892/etm.2021.9787. Epub 2021 Feb 11.
Coronavirus disease 2019 (COVID-19) is a highly infectious type of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has rapidly become a global pandemic. COVID-19, SARS and Middle East respiratory syndrome (MERS) are all caused by members of the Coronaviridae family. As expected, emerging genetic and clinical evidence from patients with COVID-19 has indicated that the pathway of infection is similar to that of SARS and MERS. Additionally, much like SARS and MERS, chest imaging serves an important role in the diagnosis, management and follow-up of patients with COVID-19. Although these related viruses present a similar pneumonic pathogenesis, the imaging results have distinguishable features. The current review evaluated the imaging results of patients with SARS and MERS and explored the potential similarities and differences among patients with COVID-19, SARS and MERS at early, progressive, severe and recovery stages, with the aim of improving our understanding of SARS-CoV-2 infections by comparing the features of COVID-19 images with those of SARS and MERS. The current review assessed whether imaging results had implications for the administration of corticosteroids as treatment for COVID-19. Whether corticosteroids can inhibit inflammatory cytokine storms and reduce the mortality of patients with viral pneumonia remains controversial. However, his review may help radiologists and clinicians to identify viral pneumonia and guide appropriate COVID-19 treatment.
2019冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的一种高传染性肺炎，已迅速成为全球大流行疾病。COVID-19、SARS和中东呼吸综合征（MERS）均由冠状病毒科的病毒引起。正如预期的那样，来自COVID-19患者的新出现的基因和临床证据表明，其感染途径与SARS和MERS相似。此外，与SARS和MERS非常相似的是，胸部影像学在COVID-19患者的诊断、管理和随访中发挥着重要作用。尽管这些相关病毒呈现出相似的肺炎发病机制，但影像学结果具有可区分的特征。本综述评估了SARS和MERS患者的影像学结果，并探讨了COVID-19、SARS和MERS患者在早期、进展期、重症期和恢复期的潜在异同，目的是通过比较COVID-19图像与SARS和MERS图像的特征，加深我们对SARS-CoV-2感染的理解。本综述评估了影像学结果是否对使用皮质类固醇治疗COVID-19有影响。皮质类固醇是否能抑制炎症细胞因子风暴并降低病毒性肺炎患者的死亡率仍存在争议。然而，本综述可能有助于放射科医生和临床医生识别病毒性肺炎并指导COVID-19的适当治疗。
